As of January 1, 2021, Dr. Julia Bridge has been appointed Director of FISH and Cytogenetics at ProPath in Dallas, TX.
Dr. Bridge will continue her role in academics and education with the department.
Cytopathology, Pathology of Bone and Soft Tissue Tumors, Molecular Pathology.
My research involves several aspects of genetics with special emphasis on cancer genetics of bone and soft tissue tumors. Over the years, we have identified a number of tumor specific chromosomal abnormalities, fusion transcripts, and/or genomic imbalances/mutations for both benign and malignant bone and soft tissue tumors as well as other solid tumors such as brain and kidney. These genetic abnormalities are important diagnostically and prognostically, as well as defining treatment strategies to include novel therapeutic targets. These data have also contributed significantly to our understanding of the histopathogenesis of many of these neoplasms..
Education and Training
BS, University of Nebraska, Lincoln, NE, 1984
MD, University of Nebraska Medical Center, Omaha, NE, 1984
Pathology Residency, University of Kansas Medical Center, Kansas City, KS, 1984-1988
Special Fellow in Cytogenetics, University of Nebraska Medical Center, University of Kansas Medical Center, 1988-1989
Molecular Biology Fellow, Southwest Biomedical Research Institute, Scottsdale, AZ, 1989-1990
National/International: Course Director/lecturer/invited speaker, molecular diagnostics, soft tissue/bone pathology, United States and Canadian Academy of Pathology (USCAP), Association for Molecular Pathology (AMP), Society for Pediatric Pathology (SPP), Connective Tissue Oncology Society (CTOS), American Academy of Orthopedic Surgeons (AAOS), Musculoskeletal Tumor Society (MSTS), College of American Pathologists (CAP), European Congress of Pathology (ECP), XXIII Pathology Meeting of A.C. Camargo Cancer Center Brazil
Nebraska Pathology Society
Faculty Advisor/Department Graduate committee
Residents/Fellows – cytopathology, cytogenetics, molecular pathology
Cytology Technologist Students - cytopathology
Medical Students – PBL,small groups facilitator, elective rotations
Digital/web-based - Oakstone, CAP
President, International Society of Bone and Soft Tissue Pathology (ISBSTP)
Secretarial Appointee to the Department of Veterans Affairs (VA) Genomic Medicine Program Advisory Committee
World Health Organization Classification (WHO) of Tumours of Soft Tissue and Bone Working Group and Editor
United States and Canadian Academy of Pathology (USCAP) Nominating Committee & Foundation Committee
Childrens Oncology Group (COG) Soft Tissue Sarcoma and Ewing Sarcoma Committees
College of American Pathologists (CAP)/American College of Medical Genetics (ACMG) Cytogenetics Resource Committee
College of American Pathologists (CAP)/ International Association for the Study of Lung Cancer (IASLC)/Association of Molecular Pathology (AMP) Lung Biomarker Advisory Panel
College of American Pathologists (CAP) Molecular Oncology Committee
College of American Pathologists (CAP) Cancer Biomarker Reporting Committee, melanoma
Editorial Board, Cancer Genetics
Editorial Board, Cancer Cytopathology
Editorial Board, Modern Pathology
Alpha Omega Alpha Honor Medical Society
Kim AS, AN Bartley, Bridge JA, Kamel-Reid S, Lazar AJ, Linderman NI, Long TA, Merker TD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR and KRAS Testing. JAMA Oncol. Dec. 2017. [Epub ahead of print] PMID: 29242895.
Nagarajan R, Bartley AN, Bridge JA, Jennings LJ, Kamel-Reid S, Kim A, Lazar AJ, Lindeman NI,Moncur J, Rai AJ, Routbort MJ, Vasalos P, Merker JD. A Window into Clinical Next Generation Sequencing based Oncology Testing Practices.across Molecular Diagnostic Laboratories. Arch Pathol Oct 2017. [Epub ahead of print] PMID: 29028368.
Wallace E, Higuchi R, Satya M, McCann L, Sin ML, Bridge JA, Wei H, Zhang J, Wong E, Hiar A,Mach KE, Scherr D, Egerdie RB, Ohta S, Sexton WJ, Meng MV, Weizer AZ, Woods M, Jansz GK, Zadra J, Lotan Y, Liao JC. Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection. J Urol Oct 2017 [Epub ahead of print] PMID: 29061538
Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O, Bridge JA, Brohl A, Stavas M, Shinohara ET, Meyer WH, Reed DR, Wagner LM. Consensus Treatment Guidelines for the treatment of Rhabdomyosarcoma. Ped Blood Cancer Sep 2017. PMID: 28905489.
Torabi A, Corral J, Gatalica Z, Swensen J, Moraveji S, Bridge JA. Primary Renal Sclerosing Epithelioid Fibrosarcoma: A Case Report and Review of the Literature. Pathology April 2017. pii: S0031-3025(16)40572-6. June 2017. PMID: 28450092
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-Institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol [Epub ahead of print March 9, 2017] Aug 2017. PMID: 28278348.
McGregor SM, Alikhan MB, John RA, Kotler H, Bridge JA, Mujacic I, Kadri S, Segal J, Krausz T. Melanotic PEComa of the Sinonasal Mucosa with NONO-TFE3 Fusion: An Elusive Mimic of Sinonasal Melanoma. Am J Surg Pathol, May 2017. PMID: 28009605.
Zajicek AK, Bridge JA, Akers JW, McGarry SV, Walker CW. Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. Skeletal Radiol. ;46(2):265-271.[Epub Dec 1 2016] Feb 2017. PMID: 27909788
Bridge JA. Reverse transcription-polymerase chain reaction molecular testing of cytology specimens: Pre-analytic and analytic factors. Cancer;125(1):11-19.[Epub Jul 14, 2016]. Jan 2017. PMID: 27412734
Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, Jin L, Chen J, Zhou H, Wang J, Zhang H, Yang N, Bradley EW, Ho TH, Rubin BP, Bridge JA, Thibodeau SN, Ordog T, Chen Y, van Wijnen AJ, Oliveira, AM. XU RM, Westendorf JJ, Zhang Z. The histone H3.3K36M mutation reprograms the epigenome of chondroplastomas. Science 10;352(6291):1344-8. [Epub 2016 May]. June 2016. PMID: 27229140
Lerman DM, Monument MJ, McLlvaine E, Xiao-qiong L, Hunag D, Monovich L, Beeler N, Gorlick RG, Marina NM, Wormer RB, Bridge JA, Kraiol MD, Randall RL, Lessnick SL. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer.;62(5):759-65. May 2015. PMID: 26449317.
For a detailed list of publications, click here.